Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability-Reference-Cited by-同舟云学术

Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability

Published:2018-08-29 Issue:456 Volume:10 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

King Andrew J.¹^ORCID,Siegel Matthew¹,He Ying¹^ORCID,Nie Baoming¹^ORCID,Wang Ji¹,Koo-McCoy Samantha¹^ORCID,Minassian Natali A.¹^ORCID,Jafri Qumber¹^ORCID,Pan Deng¹,Kohler Jill¹^ORCID,Kumaraswamy Padmapriya¹^ORCID,Kozuka Kenji¹,Lewis Jason G.¹,Dragoli Dean¹^ORCID,Rosenbaum David P.¹^ORCID,O’Neill Debbie²^ORCID,Plain Allein²^ORCID,Greasley Peter J.³^ORCID,Jönsson-Rylander Ann-Cathrine⁴^ORCID,Karlsson Daniel⁴^ORCID,Behrendt Margareta⁴^ORCID,Strömstedt Maria⁴,Ryden-Bergsten Tina⁵,Knöpfel Thomas⁶,Pastor Arroyo Eva M.⁶,Hernando Nati⁶,Marks Joanne⁷^ORCID,Donowitz Mark⁸,Wagner Carsten A.⁶^ORCID,Alexander R. Todd²^ORCID,Caldwell Jeremy S.¹^ORCID

Affiliation:

1. Ardelyx Inc., Fremont, CA 94555, USA.

2. University of Alberta, Edmonton, Alberta T6G 1C9, Canada.

3. Cardiovascular and Metabolic Disease (CVMD) Translational Medicine Unit, Early Clinical Development, Innovative Medicines and Early Development (IMED) Biotech Unit, AstraZeneca Gothenburg, 431 50 Mölndal, Sweden.

4. Bioscience, CVMD, IMED Biotech Unit, AstraZeneca Gothenburg, 431 50 Mölndal, Sweden.

5. CVMD, IMED Biotech Unit, AstraZeneca Gothenburg, 431 50 Mölndal, Sweden.

6. Institute of Physiology, University of Zurich and National Center of Competence in Research Kidney Control of Homeostasis, CH-8057 Zurich, Switzerland.

7. Department of Neuroscience, Physiology and Pharmacology, University College London, Royal Free Campus, London NW3 2PF, UK.

8. Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.

Abstract

Tenapanor inhibits sodium/hydrogen exchanger isoform 3 to reduce intestinal phosphate absorption via reduction of passive paracellular phosphate flux.

Funder

Ardelyx, Inc.

The Kidney Foundation of Canada

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference71 articles.

1. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD);Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group;Kidney Int. Suppl.,2009

2. Absorption of Inorganic Phosphate in the Human Small Intestine

3. Absorption of phosphate in the jejunum of patients with chronic renal failure before and after correction of vitamin D deficiency

4. Effect of hypophysectomy on intestinal phosphate absorption in rats

5. Characterization of intestinal phosphate absorption using a novel in vivo method

Cited by 108 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects on calcium phosphate homeostasis after sodium-glucose cotransporter 2 inhibitor in patients with advanced chronic kidney disease and type 2 diabetes mellitus;Diabetes Research and Clinical Practice;2024-10

2. Pathogenesis and Mechanism of Uremic Vascular Calcification;Cureus;2024-07-17

3. Navigating How to Initiate Tenapanor Therapy in the Real World;Kidney360;2024-07

4. Tenapanor: A Phosphate Absorption Inhibitor for the Management of Hyperphosphatemia in Patients With Kidney Failure;Journal of Renal Nutrition;2024-07

5. Management of Chronic Heart Failure in Dialysis Patients: A Challenging but Rewarding Path;Reviews in Cardiovascular Medicine;2024-06-25